Browsing by Author "Marx, F. M."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- ItemPost-tuberculosis lung health : perspectives from the First International Symposium(International Union Against Tuberculosis and Lung Disease, 2020-08-01) Allwood, B. W.; van der Zalm, M. M.; Amaral, A. F. S.; Byrne, A.; Datta, S.; Egere, U.; Evans, C. A.; Evans, D.; Gray, D. M.; Hoddinott, G.; Ivanova, O.; Jones, R.; Makanda, G.; Marx, F. M.; Meghji, J.; Mpagama, S.; Pasipanodya, J. G.; Rachow, A.; Schoeman, I.; Shaw, J.; Stek, C.; van Kampen, S.; von Delft, D.; Walker, N. F.; Wallis, R. S.; Mortimer, K.ALTHOUGH CURABLE, TB frequently leaves the individual with chronic physical and psycho-social impairment, but these consequences have been largely neglected. The 1st International Post-Tuberculosis Symposium (Stellenbosch, South Africa) was held to discuss priorities and gaps in addressing this issue. A barrier to progress has been the varied terminology and nomenclature, so the Delphi process was used to achieve consensus on definitions. Lack of sufficient evidence hampered definitive recommendations in most domains, including prevention and treatment of post-TB lung disease (PTLD), but the discussions clarified the research needed. A consensus was reached on a toolkit for future PTLD measurement and on PTLD patterns to be considered. The importance of extra-pulmonary consequences and progressive impairment throughout the life-course was identified, including TB recurrence and increased mortality. Patient advocates emphasised the need to address the psychological and social impacts post TB and called for clinical guidance. More generally, there is an urgent need for increased awareness and research into post-TB complications.
- ItemVariation in HIV prevalence and the population-level effects of antiretroviral therapy in reducing tuberculosis incidence in South Africa(Health & Medical Publishing Group, 2018) Sloot, R.; Maarman, G. J.; Osman, M.; Marx, F. M.The current year (2018) marks the 10th year after the tuberculosis (TB) epidemic in South Africa (SA) reached a historic peak of 848 incident TB cases per 100 000 population in 2008.[1,2] TB incidence has since decreased at an average of 2.0% annually to 781 per 100 000 in 2016.[1,2] The decline observed in the past decade has mainly been attributed to the expansion of HIV testing and antiretroviral therapy (ART).[1,2] Despite these and other public health efforts, TB remains a leading cause of death in SA,[1] and at the current rate of decline, SA will not reach the 2035 targets of the End TB Strategy.